Capture réglementaire en temps de pandémie
In the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. This gave the company seven years of market exclusivity for its drug in the US market....
Saved in:
Main Author: | Samira Guennif |
---|---|
Format: | Article |
Language: | English |
Published: |
Association Recherche & Régulation
2021-02-01
|
Series: | Revue de la Régulation |
Subjects: | |
Online Access: | https://journals.openedition.org/regulation/17621 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Consortium-driven rapid software validation for Research Electronic Data Capture (REDCap)
by: Theresa A. Baker, et al.
Published: (2025-01-01) -
Les femmes en temps de pandémie dans les médias
by: Martin Blanc, et al.
Published: (2024-12-01) -
INNOVATIVE PROCESSES IN THE RUSSIAN PHARMACEUTICAL MARKET
by: E. A. Bykova
Published: (2020-09-01) -
The strategy to control the outbreak of an emerging respiratory infectious disease in a simulated Chinese megacity
by: Zhiqun Lei, et al.
Published: (2025-01-01) -
Understanding the regulatory-procurement interface for medicines in Africa via publicly available information on standards, implementation, and enforcement in five countries
by: Jillian C. Kohler, et al.
Published: (2025-12-01)